陆静波, 王颖异, 张森, 李建萍, 李成曦, 徐雪君, 彭印, 陈晨凯, 郭建明, 段金廒. 黄葵四物方调控肠道菌群中代谢通路干预尿毒素合成的作用机制研究J. 药学学报, 2020,55(6): 1229-1236. doi: 10.16438/j.0513-4870.2019-0852
引用本文: 陆静波, 王颖异, 张森, 李建萍, 李成曦, 徐雪君, 彭印, 陈晨凯, 郭建明, 段金廒. 黄葵四物方调控肠道菌群中代谢通路干预尿毒素合成的作用机制研究J. 药学学报, 2020,55(6): 1229-1236. doi: 10.16438/j.0513-4870.2019-0852
LU Jing-bo, WANG Ying-yi, ZHANG Sen, LI Jian-ping, LI Cheng-xi, XU Xue-jun, PENG Yin, CHEN Chen-kai, GUO Jian-ming, DUAN Jin-ao. Huang-Kui-Si-Wu Formula decreases uremic toxin production by modulating intestinal microbial metabolic pathwaysJ. Acta Pharmaceutica Sinica, 2020,55(6): 1229-1236. doi: 10.16438/j.0513-4870.2019-0852
Citation: LU Jing-bo, WANG Ying-yi, ZHANG Sen, LI Jian-ping, LI Cheng-xi, XU Xue-jun, PENG Yin, CHEN Chen-kai, GUO Jian-ming, DUAN Jin-ao. Huang-Kui-Si-Wu Formula decreases uremic toxin production by modulating intestinal microbial metabolic pathwaysJ. Acta Pharmaceutica Sinica, 2020,55(6): 1229-1236. doi: 10.16438/j.0513-4870.2019-0852

黄葵四物方调控肠道菌群中代谢通路干预尿毒素合成的作用机制研究

Huang-Kui-Si-Wu Formula decreases uremic toxin production by modulating intestinal microbial metabolic pathways

  • 摘要: 黄葵四物方可通过减少慢性肾病(chronic kidney disease,CKD)大鼠体内尿毒素分子硫酸对甲酚(p-cresyl sulfate,PCS)及其前体对甲酚(p-cresol,PC)的蓄积来延缓CKD进程。但黄葵四物方减少对甲酚蓄积的作用机制尚不明确。本研究以对甲酚在肠道菌群中的代谢途径为切入点,探究黄葵四物方对肠道菌群生成对甲酚的影响并探讨其作用环节。采用5/6肾脏切除方法构建CKD模型大鼠,运用16S rDNA测序方法分析肠道菌群丰度和结构,结果发现黄葵四物方并不是通过直接抑制肠道菌群丰度来降低对甲酚合成的。动物实验遵循南京中医药大学动物伦理委员会规定。进一步通过建立肠道细菌体外厌氧培养体系以及HPLC-UV-FLD分析方法评价黄葵四物方对肠道菌群合成对甲酚代谢途径的影响。结果显示,黄葵四物方(4 000、400和40 μg·mL-1)可剂量依赖性抑制肠道菌群中对甲酚生成,其作用途径主要包括两条:其一,黄葵四物方促使酪氨酸代谢过程中氧化途径向还原途径转化,导致氧化途径代谢产物所占百分比由82.83%降至38.87%,还原途径代谢产物所占百分比由17.17%升至61.13%,最终导致氧化途径中对甲酚的生成显著减少。其二,黄葵四物方对生成对甲酚的氧化途径还具有直接的抑制作用,直接抑制对羟基苯乙酸分解生成对甲酚,抑制率高达90.01%。本研究提示黄葵四物方可通过调控肠道菌群中尿毒素代谢通路,多环节抑制肠道菌群中尿毒素前体生成,缓解尿毒素蓄积症状而延缓CKD进程。

     

    Abstract: Huang-Kui-Si-Wu Formula (HKSWF) can reduce the accumulation of uremic toxin p-cresyl sulfate (PCS) and its precursor p-cresol (PC) in a rat model of chronic kidney disease (CKD) and delay the progression of CKD. However, the mechanism by which HKSWF decreases PC accumulation is not clear. This study investigated the effect of HKSWF on PC production in intestinal microbes as well as its mechanism of action. After CKD model rats were given HKSWF by intragastric administration, feces were collected to analyze the gut bacterial composition by 16S rDNA sequencing technology. All procedures were approved by the Institutional Animal Care and Use Committee of the Nanjing University of Chinese Medicine. The results showed that HKSWF inhibited PC production without decreasing the abundance of harmful bacteria. HPLC-UV-FLD was used to detect p-cresol. An in vitro anaerobic culture system was used to study the effect and mechanism of action of HKSWF on PC production in gut bacteria. The results show that food-derived tyrosine (Tyr) could significantly promote PC production in intestinal bacteria, and HKSWF (4000, 400, 40 μg·mL-1) could dose-dependently inhibit PC production in gut bacteria in vitro. HKSWF inhibited bacterial PC synthesis by two pathways: it decreased the oxidation pathway from 82.83% to 38.87%, and increased the reductive pathway from 17.17% to 61.13%. This result suggests that HKSWF could inhibit PC production by switching tyrosine metabolism from an oxidative pathway to a reductive pathway. Secondly, HKSWF could directly inhibit the oxidative pathway of tyrosine and decrease the decomposition of PHA, thereby inhibiting PC production. These results suggest that HKSWF could inhibit the formation of harmful uremic toxins by modulating the metabolic pathway of PC in gut microbiota and thereby delaying CKD progression.

     

/

返回文章
返回